CMPI Report: Principles for Patient-Centered Prescription Drug Coverage

N/A by N/A is licensed under N/A N/A

Read the Report here.


Principles for Patient-Centered Prescription Drug Coverage

Monday, September 11, 2017  
8:30am – 1:30 pm
National Press Club
Holeman Lounge
529 14th St NW
Washington, DC 20045
 
Panel One:     How PBMs Affect Access and Affordability
 
Moderator:     Peter J. Pitts, President, CMPI
Panelists:         B. Douglas Hoey, CEO, National Community Pharmacists Association
                          Nick Ferreyros, Director of Communications, Community Oncology Alliance
                          Derek Daggett, Senior Business Development Executive, SmithRx

Watch Panel One highlights here.

Keynote Speaker: A. Mark Fendrick, M.D., Director, Center for Value Based Insurance Design, University of Michigan
Introduction by Robert M. Goldberg, CMPI

Watch Dr. A. Mark Fendrick's Keynote Remarks here.

Panel Two:     Principles for PBM Reform and Patient-Centered Prescription Drug Benefits
 
Moderator:   Robert M. Goldberg, PhD, Vice President, CMPI
Panelists:       Shawn Lovering, President, RxTE
                        Susan Pilch, Vice President, Policy & Regulatory Affairs, NCPA
                        A. Mark Fendrick, M.D., University of Michigan
                        Burt Zweigenhaft, Managing Partner, Upstream Partners
 
Watch Panel Two highlights here.
Article Photo Credit: N/A by N/A is licensed under N/A N/A
Sign Up for Our Email Newsletter

RECENT NEWS

Vaper Madness

Vaper Madness

E-cigarettes, while not a cure for nicotine dependence, can help reduce the death and disease caused by combustible tobac...  Read more

Three ways Congress can lower seniors’ pharmacy bills

Three ways Congress can lower seniors’ pharmacy bills

Here are three ways Congress can improve Medicare Part D to lower seniors’ drug tabs....  Read more

FDA Hears Concerns About The Unregulated CBD Market

FDA Hears Concerns About The Unregulated CBD Market

What most speakers agreed on: the need for federal CBD oversight for production quality, more testing and research and be...  Read more

DRUGWONKS BLOG